193 related articles for article (PubMed ID: 10901362)
1. Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.
Ford HE; Cunningham D; Ross PJ; Rao S; Aherne GW; Benepal TS; Price T; Massey A; Vernillet L; Gruia G
Br J Cancer; 2000 Jul; 83(2):146-52. PubMed ID: 10901362
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Lewis NL; Scher R; Gallo JM; Engstrom PF; Szarka CE; Litwin S; Adams AL; Kilpatrick D; Brady D; Weiner LM; Meropol NJ
Cancer Chemother Pharmacol; 2002 Oct; 50(4):257-65. PubMed ID: 12357298
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
Aparicio J; de las Peñas R; Vicent JM; Garcerá S; Llorca C; Maestu I; Yuste AL; Farrés J
Oncology; 2002; 63(1):42-7. PubMed ID: 12187070
[TBL] [Abstract][Full Text] [Related]
4. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.
Fizazi K; Ducreux M; Ruffié P; Bonnay M; Daniel C; Soria JC; Hill C; Fandi A; Poterre M; Smith M; Armand JP
J Clin Oncol; 2000 Jun; 18(11):2293-300. PubMed ID: 10829050
[TBL] [Abstract][Full Text] [Related]
5. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
Scheithauer W; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Gedlicka C; Schüll B; Brugger S; Schneeweiss B; Lang F; Lenauer A; Depisch D
J Clin Oncol; 2002 Jan; 20(1):165-72. PubMed ID: 11773166
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial.
Scheithauer W; Kornek GV; Ulrich-Pur H; Penz M; Raderer M; Salek T; Haider K; Kwasny W; Depisch D
Cancer; 2001 Apr; 91(7):1264-71. PubMed ID: 11283925
[TBL] [Abstract][Full Text] [Related]
7. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Sastre J; Paz-Ares L; Carcas A; Alfonso R; Grávalos C; Frías J; Guerra P; Pronk L; Cortés-Funes H; Díaz-Rubio E
Cancer Chemother Pharmacol; 2005 May; 55(5):453-60. PubMed ID: 15818508
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer.
Chiara S; Nobile MT; Tomasello L; Acquati M; Taveggia P; Murolo C; Percivale P; Rosso R
Anticancer Res; 2005; 25(2B):1391-6. PubMed ID: 15865096
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.
Aparicio J; Vicent JM; Maestu I; Bosch C; Galán A; Busquier I; Llorca C; Garcerá S; Campos JM; López-Tendero P; Balcells M
Oncology; 2005; 68(1):58-63. PubMed ID: 15809521
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Masi G; Falcone A; Di Paolo A; Allegrini G; Danesi R; Barbara C; Cupini S; Del Tacca M
Clin Cancer Res; 2004 Mar; 10(5):1657-63. PubMed ID: 15014016
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.
Stevenson JP; Redlinger M; Kluijtmans LA; Sun W; Algazy K; Giantonio B; Haller DG; Hardy C; Whitehead AS; O'Dwyer PJ
J Clin Oncol; 2001 Oct; 19(20):4081-7. PubMed ID: 11600611
[TBL] [Abstract][Full Text] [Related]
12. A dose-finding study for oxaliplatin, irinotecan, and S-1 (OIS) in patients with metastatic or recurrent gastrointestinal cancer.
Han B; Jung JY; Kim HS; Cho JW; Kim KC; Lim H; Kang HS; Ha HI; Kim MJ; Kim JH; Choi DR; Jang G; Kim JH; Song H; Zang DY
Cancer Chemother Pharmacol; 2016 Nov; 78(5):949-958. PubMed ID: 27628195
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
Ulrich-Pur H; Raderer M; Verena Kornek G; Schüll B; Schmid K; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Scheithauer W
Br J Cancer; 2003 Apr; 88(8):1180-4. PubMed ID: 12698181
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.
Horton TM; Blaney SM; Langevin AM; Kuhn J; Kamen B; Berg SL; Bernstein M; Weitman S
Clin Cancer Res; 2005 Mar; 11(5):1884-9. PubMed ID: 15756014
[TBL] [Abstract][Full Text] [Related]
15. Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
Tsavaris N; Kosmas C; Vadiaka M; Koufos C
BMC Cancer; 2002; 2():2. PubMed ID: 11860608
[TBL] [Abstract][Full Text] [Related]
16. [Absence of cross resistance between an irinotecan plus cisplatin combination and raltitrexed (ZD1694) in two patients with advanced colorectal cancer].
Sato A; Kurihara M; Matsukawa M; Yamazaki T; Shimada K; Endo W; Yamazaki T; Nakamachi M
Gan To Kagaku Ryoho; 2000 Apr; 27(4):617-21. PubMed ID: 10791007
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
Chester JD; Joel SP; Cheeseman SL; Hall GD; Braun MS; Perry J; Davis T; Button CJ; Seymour MT
J Clin Oncol; 2003 Mar; 21(6):1125-32. PubMed ID: 12637480
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of a fixed dose of cisplatin with increasing doses of raltitrexed (Tomudex) in the treatment of patients with locally advanced or metastatic squamous cell carcinoma of the head and neck.
ten Bokkel Huinink D; Tesselaar ME; Baatenburg de Jong RJ; Verschuur HP; Keizer HJ
Ann Oncol; 2001 Mar; 12(3):357-63. PubMed ID: 11332149
[TBL] [Abstract][Full Text] [Related]
20. Raltitrexed ('Tomudex') and radiotherapy can be combined as postoperative treatment for rectal cancer.
Botwood N; James R; Vernon C; Price P
Ann Oncol; 2000 Aug; 11(8):1023-8. PubMed ID: 11038040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
